Clinical Trial News and Research RSS Feed - Clinical Trial News and Research

Promising molecular diagnostic approach to endometriosis

Promising molecular diagnostic approach to endometriosis

Researchers at UC San Francisco have identified patterns of genetic activity that can be used to diagnose endometriosis and its severity, a finding that may offer millions of women an alternative to surgery through a simple noninvasive procedure. [More]
Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]
Self-acupressure may be effective for treating constipation

Self-acupressure may be effective for treating constipation

About 19 percent of North Americans suffer from constipation, with the digestive condition being more common among women, non-whites, people older than 60, those who are not physically active and the poor. [More]
Model G: New patient hospital gown blends style and comfort

Model G: New patient hospital gown blends style and comfort

A new Detroit design is rolling off the assembly line in the Motor City in 2015, made with a cotton-poplin blend for comfort, color-coded trim for ease of use and - most importantly - a closed backside that finally offers patients more privacy and comfort in the hospital. [More]
Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals. [More]
Scientists discover second wave of heart muscle inflammation within a week after heart attack

Scientists discover second wave of heart muscle inflammation within a week after heart attack

Results of a new study challenge the current consensus in cardiology that peak myocardial edema, or heart muscle swelling, only occurs just after a myocardial infarction, or heart attack. In the study, presented as a Late-Breaking Clinical Trial at the American Heart Association Scientific Sessions 2014 and published simultaneously in the Journal of the American College of Cardiology, scientists discovered a second wave of swelling and inflammation occurs within a week of a heart attack. [More]
Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found. [More]
Biomarker-directed chemotherapy detrimental in NSCLC

Biomarker-directed chemotherapy detrimental in NSCLC

Treating non-small-cell lung cancer patients with chemotherapy customised according to expression of BRCA1 and receptor-associated protein 80 does not improve progression-free survival compared with nonselected, cisplatin-based chemotherapy, show study findings. [More]
Great Basin Scientific seeks FDA approval for Group B Strep assay

Great Basin Scientific seeks FDA approval for Group B Strep assay

Great Basin Scientific, Inc., a molecular diagnostics company, today announced it has submitted its Group B Strep assay to the U.S. Food and Drug Administration for 510(k) clearance. [More]
Cardiac stem cell treatment restores heart function damaged by Duchenne muscular dystrophy

Cardiac stem cell treatment restores heart function damaged by Duchenne muscular dystrophy

Researchers at the Cedars-Sinai Heart Institute have found that injections of cardiac stem cells might help reverse heart damage caused by Duchenne muscular dystrophy, potentially resulting in a longer life expectancy for patients with the chronic muscle-wasting disease. [More]
Investigational treatment shows promise against Marfan syndrome

Investigational treatment shows promise against Marfan syndrome

An investigational treatment for Marfan syndrome is as effective as the standard therapy at slowing enlargement of the aorta, the large artery of the heart that delivers blood to the body, new research shows. The findings indicate a second treatment option for Marfan patients, who are at high risk of sudden death from tears in the aorta. [More]
Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada is aware of and will be reviewing new evidence on the safety of long-term use of the prescription blood-thinners clopidogrel (Plavix) and prasugrel (Effient). [More]
TapImmune signs new collaborative research agreement with VGTI Florida

TapImmune signs new collaborative research agreement with VGTI Florida

TapImmune, Inc., is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida, a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers. [More]
New oral medication shows promise in treating fibromyalgia

New oral medication shows promise in treating fibromyalgia

A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial. [More]
Adding ezetimibe to statin therapy reduces cardiovascular events

Adding ezetimibe to statin therapy reduces cardiovascular events

More than a decade ago, researchers from Brigham and Women's Hospital demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical outcomes. But questions remained about whether further reducing cholesterol would be even more effective in reducing cardiovascular-related events. [More]
Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone. [More]

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Anthera Pharmaceuticals, Inc., today announced financial results and operational update for the third quarter ended September 30, 2014. [More]
Lobectomy outweighs sublobar resection for elderly early-stage NSCLC patients

Lobectomy outweighs sublobar resection for elderly early-stage NSCLC patients

Lobectomy may the best option for elderly patients with early-stage non-small-cell lung cancer who are able to undergo surgery, say researchers from the US. [More]
No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

The irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor dacomitinib does not offer a survival benefit in pretreated patients with advanced or metastatic non-small-cell lung cancer, phase III trial results show. [More]
CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, today reported financial results for the three and nine months ended September 30, 2014. [More]